Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Acylated Glucagon-like Peptide-1 Receptor Agonist

Catalog No.: YR0141

Basic Information

Molecular Weight
3.8 kDa

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SDS-PAGE

Background

Liraglutide, a recombinant peptide which presents 97% homology with human glucagon-like peptide-1 (GLP-1), differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide is resistant to the dipeptidylpeptidase-4 enzyme whic degrades the natural hormone. As a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics, Liraglutide actives the GLP-1 receptor and exerts an incretin mimetic effect during at least 24 hours after a single subcutaneous injection. Besides a glucose-dependent stimulatory effect of insulin secretion, liraglutide inhibits glucagon secretion and retards gastric emptying. Liraglutide is an anti-diabetic medication used to treat type 2 diabetes, obesity, and chronic weight management. Liraglutide is given by injection under the skin. Liraglutide works by increasing insulin release from the pancreas and decreases excessive glucagon release.

Reported Applications

ELISA,functional assays such as bioanalytical PK and ADA assays,and those assays for studying biological pathways affected by liraglutide.

Immunogen Information

Clone
Liraglutide Biosimilar

Isotype

Immunogen

RecommendedIsotype Control(s)

Recommended Dilution Buffer
lyophilized from 0.2 μM filtered solution

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn

Product Information

Production
Purified from cell culture supernatant in an animal-free facility

Purification
Protein A or G purification

Storage
Store at -20℃